Mirabeg 25mg - Tablet Mirabegron - 25mg 10 Tablet(s) / Strip Unknown Introduction: Mirabeg 25mg is used to treat symptoms of overactive bladder that includes increased or frequent urination, urgent need to urinate and inability to control urination. It helps to relax the muscle surrounding the bladder and increase it's ability to store urine. Mirabeg 25mg is advised to take it in a dose and duration as per prescription. It can be taken with or without food. Swallow the medicine as a whole without crushing or chewing it. You should not stop taking the medicine without consulting the doctor as it may lead to the worsening of your symptoms. The course of the... Uses of Mirabeg 25mg: Overactive bladder (OAB) symptoms Side effects of Mirabeg 25mg: ConstipationHeadacheHigh blood pressureNasal inflammationUrinary tract infection How to use Mirabeg 25mg: Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Mirabeg 25mg may be taken with or without food, but it is better to take it at a fixed time. How Mirabeg 25mg works: Mirabeg 25mg is a beta 3-receptor agonist. It works by activating the receptor in the bladder, causing the bladder muscles to relax. It prevents frequent, urgent or uncontrolled urination. Indication: Overactive bladder, with symptoms of urge urinary incontinence, urgency, and urinary frequency Administration: May be taken with or without food: Swallow whole, do not chew/divide/crush. Adult Dose: Overactive Bladder Indicated for overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency 25 mg PO qDay 25 mg dose is typically effective within 8 weeks May increase to 50 mg PO qDay based on individual efficacy and tolerability Hepatic impairment Moderate (Child-Pugh B): Not to exceed 25 mg/day Severe (Child Pugh C): Not recommended Renal Dose: Renal impairment Severe (CrCl 15-29 mL/min): Not to exceed 25 mg/day ESRD: Not recommended Contraindication: Hypersensitivity. Severe uncontrolled HTN. Mode of Action: Beta-3 adrenergic receptor agonist which causes relaxation of the detrusor smooth muscle of the urinary bladder and increases bladder capacity. Precaution: End-stage renal disease, severe renal impairment; moderate (Child-Pugh Class B) & severe hepatic impairment (Child-Pugh Class C); severe uncontrolled HTN. Known history of QT prolongation or taking medicines known to prolong QT interval; bladder outlet obstruction & taking antimuscarinic medications for OAB. Women of childbearing potential not using contraception. Pregnancy & lactation. Childn <18 yr. Lactation: Unknown whether distributed in breast milk; excretion in breast milk possible; discontinue nursing or the drug taking into account the importance of the drug to the mother Side Effect: >10% Elevated BP occurring predominantly in patients with preexisting hypertension (7-11%) 1-10% Dry mouth (3-9%),Nasopharyngitis (3-4%),UTI (3-6%),Headache (2-4%),Influenza (2-3%),Constipation (2-3%),Dizziness (2%),Arthralgia (2%),Cystitis (2%),Back pain (1-3%),Sinusitis (1-3%),URTI (1-2%),Arthralgia (1-2%),Diarrhea (1-2%),Tachycardia (1-2%),Fatigue (1%),Abdominal pain (0-1%),Reports of neoplasms (0-1%) <1% Cardiac disorders (eg, palpitations, elevated BP),Eye Disorders (eg, glaucoma, blurry vision),GI disorders (eg, dyspepsia, gastritis, abdominal distension),Rhinitis,Elevations in GGT, AST, ALT, LDH, Renal and urinary disorders (eg, nephrolithiasis, bladder pain), Reproductive system disorders (eg, vulvovaginal pruritis, vaginal infection) Skin and subcutaneous tissue disorders (eg, urticaria, leukocytoclastic vasculitis, rash, pruritus, purpura, lip edema) Stevens-Johnson syndrome associated with increased serum ALT, AST and bilirubin Interaction: Increased AUC of strong CYP3A/P-gp inhibitors eg, ketoconazole, itraconazole, ritonavir, clarithromycin. Decreased plasma conc by CYP3A/P-gp inducers. Increased Cmax & AUC of metoprolol, despiramine & digoxin. Thioridazine, type 1C antiarrhythmics (eg flecainide, propafenone), TCAs. Potential P-gp inhibition of dabigatran.